Skip to search formSkip to main contentSkip to account menu

Lumigan

National Institutes of Health

Related topics

Related topics

4 relations
Brimonidine tartratebimatoprost 0.1 MG/ML Ophthalmic Solution [Lumigan]bimatoprost Ophthalmic Solution [Lumigan]

Broader (1)

bimatoprost

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Spectrofluorimetric Study on Inclusion Interaction of β- Cyclodextrin with Bimatoprost: Challenging to Green Analytical Applications
Fluorescence study on inclusion interaction of bimatoprost in absence and presence of β-cyclodextrin shows significant increase… 
2013
2013
Ocular Pharmacokinetics of ISV-215 (Bimatoprost 0.03%) Formulated in a DuraSite Delivery System Compared to Lumigan in Rabbits
2011
2011
Treatment persistency of Xalatan-Xalacom, Lumigan-Ganfort and Travatan-Duotrav: An analysis conducted on the United-Kingdom General Practitioner Research Database
2009
2009
A meta-analysis of therapy comparison between bimatoprost and timolol in ocular hypertention eye
Objective Many researches have demonstrated the lowing-intraocular pressure(IOP) effects of bimatoprost and timolol.However,no… 
2005
2005
A Prospective Comparative Switch Study From Xalacom (Timolol 0.5% + Latanoprost 0.005%) to Lumigan (Bimatoprost 0.03%)
2004
2004
Análisis coste-eficacia hipotensora de los fármacos antiglaucomatosos más utilizados
espanolObjetivo: Evaluar el coste/ano y el coste/eficacia hipotensora de los farmacos topicos antiglaucomatosos. Metodos: Este… 
2003
2003
Evaluation of the Stability of Xalatan and Lumigan After Dispensing and Simulated Patient Use
2003
2003
THE OCULAR HYPOTENSIVE EFFECTS OF LUMIGAN ARE UNRELATER TO MET－ABOLITE FORMATION
2002
2002
Efficacy and Safety of Bimatoprost 0.03% (LUMIGAN) in a Large-Scale, Open-Label Clinical Trial
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)